Literature DB >> 21864468

Inflaming depression.

Hymie Anisman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21864468      PMCID： PMC3163645          DOI： 10.1503/jpn.110071

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  38 in total

Review 1.  The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature.

Authors:  D De Berardis; C M V Conti; N Serroni; F S Moschetta; L Olivieri; A Carano; R M Salerno; M Cavuto; B Farina; M Alessandrini; L Janiri; G Pozzi; M Di Giannantonio
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Apr-Jun       Impact factor: 3.219

Review 2.  Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders.

Authors:  Hymie Anisman; Zul Merali; Shawn Hayley
Journal:  Prog Neurobiol       Date:  2008-02-13       Impact factor: 11.685

3.  Role of IL-1 in poststroke depressive-like behavior in mice.

Authors:  Tara K S Craft; A Courtney DeVries
Journal:  Biol Psychiatry       Date:  2006-05-30       Impact factor: 13.382

Review 4.  Exposure to acute stress induces brain interleukin-1beta protein in the rat.

Authors:  K T Nguyen; T Deak; S M Owens; T Kohno; M Fleshner; L R Watkins; S F Maier
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

Review 5.  Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?

Authors:  M Catena-Dell'Osso; C Bellantuono; G Consoli; S Baroni; F Rotella; D Marazziti
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

Authors:  Shahin Akhondzadeh; Sara Jafari; Firoozeh Raisi; Abbas Ali Nasehi; Aboulfazl Ghoreishi; Bahman Salehi; Soodeh Mohebbi-Rasa; Maedeh Raznahan; Abbas Kamalipour
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

7.  Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.

Authors:  Aric A Prather; Mordechai Rabinovitz; Bruce G Pollock; Francis E Lotrich
Journal:  Brain Behav Immun       Date:  2009-07-15       Impact factor: 7.217

8.  The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats.

Authors:  Bríana Fahey; Barry Hickey; Dermot Kelleher; Anne-Marie O'Dwyer; Shane M O'Mara
Journal:  Behav Brain Res       Date:  2007-05-22       Impact factor: 3.332

9.  Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations.

Authors:  Hymie Anisman; Michael O Poulter; Reno Gandhi; Zul Merali; Shawn Hayley
Journal:  J Neuroimmunol       Date:  2007-04-10       Impact factor: 3.478

10.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression.

Authors:  Reiji Yoshimura; Hikaru Hori; Atsuko Ikenouchi-Sugita; Wakako Umene-Nakano; Nobuhisa Ueda; Jun Nakamura
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-03-28       Impact factor: 5.067
View more
  9 in total

1.  Activation of Brain Indoleamine-2,3-dioxygenase Contributes to Depressive-Like Behavior Induced by an Intracerebroventricular Injection of Streptozotocin in Mice.

Authors:  Leandro Cattelan Souza; Cristiano R Jesse; Marcelo Gomes de Gomes; Lucian Del Fabbro; André Tiago Rossito Goes; Franciele Donato; Silvana Peterini Boeira
Journal:  Neurochem Res       Date:  2017-06-19       Impact factor: 3.996

2.  Intracerebroventricular Administration of Streptozotocin as an Experimental Approach to Depression: Evidence for the Involvement of Proinflammatory Cytokines and Indoleamine-2,3-Dioxygenase.

Authors:  Leandro Cattelan Souza; Cristiano R Jesse; Marcelo Gomes de Gomes; Cristini Escobar Viana; Etiara Mattos; Neici Cáceres Silva; Silvana Peterini Boeira
Journal:  Neurotox Res       Date:  2017-02-02       Impact factor: 3.911

Review 3.  Neuroimmunomodulation in unipolar depression: a focus on chronobiology and chronotherapeutics.

Authors:  Harris Eyre; Bernhard T Baune
Journal:  J Neural Transm (Vienna)       Date:  2012-06-01       Impact factor: 3.575

Review 4.  Fatigue in chronic inflammation - a link to pain pathways.

Authors:  Karine Louati; Francis Berenbaum
Journal:  Arthritis Res Ther       Date:  2015-10-05       Impact factor: 5.156

5.  The links between chronic obstructive pulmonary disease and comorbid depressive symptoms: role of IL-2 and IFN-γ.

Authors:  Joanna Rybka; S Mechiel Korte; Małgorzata Czajkowska-Malinowska; Małgorzata Wiese; Kornelia Kędziora-Kornatowska; Józef Kędziora
Journal:  Clin Exp Med       Date:  2015-09-24       Impact factor: 3.984

6.  Risk Factors for Depression in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Kang Xu; Xiu Li
Journal:  Med Sci Monit       Date:  2018-03-08

7.  Depression and alexithymia on weight perception in patients with metabolic syndrome and type 2 diabetes.

Authors:  Maria Cristina de Oliveira Regina; Marcos Antonio Tambascia
Journal:  Diabetol Metab Syndr       Date:  2017-05-12       Impact factor: 3.320

Review 8.  Stress-Related Immune Markers in Depression: Implications for Treatment.

Authors:  Martina M Hughes; Thomas J Connor; Andrew Harkin
Journal:  Int J Neuropsychopharmacol       Date:  2016-01-16       Impact factor: 5.176

9.  Positive Correlation of Serum N-Acetyl-β-hexosaminidase with Markers of Atherosclerosis in Diabetes Type 2 Patients with Mild Symptoms of Depression and Anxiety.

Authors:  Sylwia Chojnowska; Iwona Cabaj-Wiater; Aleksandra Mikulska-Baran; Beata Zalewska-Szajda; Napoleon Waszkiewicz
Journal:  Dis Markers       Date:  2018-06-20       Impact factor: 3.434
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.